Mission Statement, Vision, & Core Values of Check-Cap Ltd. (CHEK)

When a company like Check-Cap Ltd. (CHEK) is forecasted to generate $0 million in annual revenue for the 2025 fiscal year, yet its shareholders approve a transformational merger with MBody AI by over 98%, you have to ask: what exactly is the mission now? This massive pivot from clinical-stage medical diagnostics to embodied artificial intelligence (AI) defintely complicates the foundational statements that once guided the C-Scan system.

How do the core values developed for non-invasive colorectal cancer screening-focused on patient care and scientific rigor-translate to a Nasdaq leader in enterprise-scale AI solutions? Let's analyze the original Mission Statement, Vision, and Core Values to see which of these principles are still relevant, and which must evolve to support a new business with a $13.87 million market capitalization and a completely different strategic trajectory.

Check-Cap Ltd. (CHEK) Overview

You need a clear picture of Check-Cap Ltd. (CHEK), and the reality is that its foundation has completely shifted. The company is in the final stages of a transformational merger, pivoting from a clinical-stage medical device firm to a leader in embodied artificial intelligence (AI). The financial analysis must be viewed through this lens, as the former business model is effectively being replaced.

Check-Cap Ltd., founded in 2005, was historically focused on developing the C-Scan® system, a non-invasive, preparation-free ingestible X-ray capsule for colorectal cancer screening. This technology aimed to improve patient compliance by offering a comfortable alternative to traditional colonoscopy. However, the company's strategic direction changed dramatically in late 2025. Following a shareholder vote on November 14, 2025, with over 98% approval, Check-Cap is merging with MBody AI, an embodied AI company. This move is expected to close in the coming weeks, marking a complete shift in the company's core business and product focus.

The new entity, MBody AI, is centered on the MBody AI Orchestrator™, a hardware-agnostic, enterprise-scale AI platform. This platform integrates and coordinates diverse robotic and sensor-based systems, enabling the automation of physical operations across sectors like healthcare, logistics, and retail. This is a massive strategic pivot, so you can't analyze the company's future using its past medical device metrics.

2025 Financial Performance: A Pre-Merger Reality Check

Honestly, the 2025 fiscal year financial data for the original Check-Cap business is the clearest indicator of why the merger was necessary. You're not looking at record-breaking revenue; you're looking at a clinical-stage company with no commercial sales. The forecasted annual revenue for the fiscal year ending December 31, 2025, is a stark $0 million. That's a zero-revenue business, which is typical for a company still in the clinical trial phase, but it definitely highlights the financial risk.

Here's the quick math on the burn rate:

• Forecasted 2025 Annual Revenue: $0 million
• Forecasted 2025 Annual EBIT Loss: -$17 million
• Forecasted 2025 Annual Loss Per Share (EPS): -$3.53

What this estimate hides is the significant financial challenge the company faced: persistent losses and a lack of revenue generation. The trailing twelve months ending December 31, 2024, saw a net loss of approximately -$25.15 million. The latest reported quarter showed total assets of just $0.38 million against total liabilities of $1.81 million. The merger is the lifeline, injecting the company into a high-growth sector to overcome this zero-revenue reality.

Emerging as a Leader in Embodied AI

The company's status as a 'leader' is not based on its former medical device work, which saw it rank low in its sector. Instead, the leadership position comes from the acquisition of MBody AI, which is described as a 'global market leader in embodied artificial intelligence.' This transformation accelerates Check-Cap's entry into a market where US enterprises are racing to roll out full-facility embodied-AI systems for significant, recurring cost savings.

The new company's value proposition is its platform-level approach, the MBody AI Orchestrator™, which enables clients to automate physical operations with reduced risk and measurable Return on Investment (ROI). This strategic move positions the new entity as one of the only true embodied AI companies on Nasdaq, ready to capitalize on the shift from robotics pilots to enterprise-scale AI adoption. To understand the full implications of this pivot and the financial health of the new entity, you need to dive deeper. Find out more about the financial implications of this strategic shift in Breaking Down Check-Cap Ltd. (CHEK) Financial Health: Key Insights for Investors.

Check-Cap Ltd. (CHEK) Mission Statement

You are looking at Check-Cap Ltd. (CHEK) right at a pivotal moment, so you need to understand the mission has fundamentally changed. The company is transitioning from a clinical-stage medical diagnostics firm to a leader in embodied artificial intelligence (AI) following the shareholder-approved merger with MBody AI Corp. on November 17, 2025. The new mission, which guides the combined entity-soon to be renamed MBody AI Ltd.-is clear: Simplify AI adoption and transform everyday operations with measurable impact.

This strategic shift is a direct response to the market reality. The legacy business had a forecasted annual revenue of $0 million for the 2025 fiscal year, making the pivot a necessity for long-term viability. The new mission is now aligned with a high-growth sector, positioning the company to capture value in a market projected to reach $3.24 billion in 2025 globally. That's a massive change in focus, from a niche medical device to a foundational AI platform.

Core Component 1: Simplify AI Adoption for Enterprise

The first core component centers on making complex, real-world AI accessible to large organizations. This is achieved through the proprietary MBody AI Orchestrator™ platform, which acts as a foundational layer for the 'embodied AI' economy (AI systems integrated into physical entities like robots). The goal is to move beyond siloed robotics pilots to full-facility automation.

The platform's key value proposition is being hardware-agnostic, meaning it can integrate and coordinate diverse robots and sensor systems from any manufacturer. This cuts out the costly, custom integration work that typically stalls enterprise-level automation. The company is essentially building the operating system for the autonomous workforce of the future. The U.S. Embodied AI market alone is projected to hit $1.1 billion in 2025, showing the scale of the opportunity for a simplified, unifying platform.

• Integrate diverse robotic systems easily.
• Unify sensors and machines into one intelligent network.
• Enable rapid, enterprise-wide AI deployment.

Core Component 2: Transform Everyday Operations

The second component is about delivering tangible, operational change, not just selling software. The mission promises to 'transform everyday operations,' which means automating physical tasks across multiple, high-friction industries. The company is already powering Fortune 500 enterprises and blue-chip clients in sectors like hospitality, healthcare, logistics, retail, and data centers.

The transformation is backed by hard numbers. Organizations using the MBody AI Orchestrator™ have reported significant operational improvements, including up to a 40 percent labor reduction and an 80 percent uptime improvement. Here's the quick math: if a client saves 40% on labor costs in a large warehouse operation, the platform pays for itself very quickly. This focus on operational excellence is the defintely the new definition of 'high-quality product' for the company.

For more context on the financial health that necessitated this massive strategic pivot, you should read Breaking Down Check-Cap Ltd. (CHEK) Financial Health: Key Insights for Investors.

Core Component 3: Deliver Measurable Impact

The final pillar of the mission-'with measurable impact'-is the financial and strategic anchor. It's a commitment to generating clear Return on Investment (ROI) for clients and scalable revenue for the company. The market is ready: the Embodied AI robot segment is expected to hold the largest market share in 2025 at 36.0%, proving that the demand for physical-world automation is strong.

For investors, this measurable impact is crucial. The merger structure itself reflects a clear valuation of the new business, with MBody AI shareholders receiving 90% of the combined company's fully diluted share capital. This tells you the market is pricing in the high-growth potential of the AI platform over the legacy assets. The new focus is on generating significant, recurring cost savings for clients, which translates into scalable, predictable subscription revenue for the company. That's the kind of financial clarity a seasoned analyst looks for.

Check-Cap Ltd. (CHEK) Vision Statement

You need to understand that the Check-Cap Ltd. (CHEK) you knew a few months ago is fundamentally gone. The vision has completely shifted. The company's future is no longer in medical diagnostics; it's in artificial intelligence. The shareholders approved a transformational merger with MBody AI Corp. on November 14, 2025, with over 98% of votes in favor, effectively changing the company's strategic course to become a leader in embodied AI.

This pivot was a necessity. As a clinical-stage company, Check-Cap's forecasted annual revenue for the 2025 fiscal year is $0 million, and the estimated annual EBIT (Earnings Before Interest and Taxes) is a loss of -$17 million. That kind of cash burn forces a change. The new vision, which will soon operate under a new name like MBody AI Ltd., is built on three pillars that map directly to high-growth enterprise technology.

Here's the quick math on the pivot: the market capitalization was around $13.87 million just before the merger closed. You don't make a dent in the Nasdaq with a valuation that small unless you execute a radical change, and that's exactly what the board did. For more on the investors who backed this move, I suggest reading Exploring Check-Cap Ltd. (CHEK) Investor Profile: Who's Buying and Why?

Pillar 1: Embodied AI Market Leadership

The core of the new vision is simple: be the definitive leader in embodied artificial intelligence (AI) on the Nasdaq. Embodied AI isn't just software; it's the intelligence that integrates and coordinates diverse robots and sensor-based systems in the physical world, creating an autonomous workforce. This is a massive, multi-sector opportunity.

The strategic goal is to move beyond the old C-Scan capsule's niche market-colorectal cancer screening-and into a platform that can automate physical operations across hospitality, healthcare, logistics, and retail. This shift targets a market where U.S. enterprises are racing to roll out full-facility automation for significant, recurring cost savings. The old mission of 'patient-centric solutions' is being replaced by a mission of 'enterprise-scale operational excellence.'

• Integrate diverse robotic systems.
• Automate physical operations at scale.
• Deliver measurable ROI (Return on Investment) for clients.

Pillar 2: Hardware-Agnostic Platform Innovation

The second pillar focuses on technological flexibility and scale. The company's new flagship product is the MBody AI Orchestrator™, which is a hardware-agnostic platform. This means it can integrate with any robot or sensor system, not just a proprietary one. This is defintely the smart play.

Think of it like the cloud computing revolution: software became hardware-agnostic, and that unlocked massive growth. The new vision aims to do the same for physical automation. This approach reduces client risk and speeds up deployment, which is a huge competitive advantage in the enterprise space. The old C-Scan system was a single, proprietary piece of hardware; the new platform is an ecosystem.

Pillar 3: Financial Transformation and Value Creation

The final, and most crucial, pillar is financial. The merger is a direct response to the financial challenges of a clinical-stage company with no commercial revenue. The new vision is to capitalize on the growing demand for enterprise-scale AI solutions, which promises significant cost savings and operational efficiencies for customers.

The company is trading on the promise of future growth, not current earnings. Analysts are forecasting an annual loss of -$3.53 per share for the 2025 fiscal year. The core value here is a shift from a long, uncertain regulatory path for a medical device to a faster, recurring-revenue model in enterprise software. The new leadership's immediate action is to close the merger and execute the rebrand, leveraging the 98.01% shareholder approval as a mandate for this radical change.

Check-Cap Ltd. (CHEK) Core Values

You're looking for the bedrock principles that guide a company, especially one in the middle of a major strategic shift. For Check-Cap Ltd., the core values-though often unstated in a formal, bulleted list-have always mapped directly to their mission: revolutionizing colorectal cancer (CRC) screening. But as of November 2025, these values must be viewed through the lens of the approved merger with MBody AI Corp, a move that fundamentally changes their operating model.

The company's commitment to its founding principles is now demonstrated by how it navigates this pivot. It's not just about the C-Scan system anymore; it's about translating that initial drive into a new, artificial intelligence (AI)-focused healthcare venture. Honestly, this kind of pivot shows a different kind of conviction than simply pushing a single product.

Patient-Centric Innovation

The core of Check-Cap Ltd.'s original mission was to create a non-invasive, preparation-free solution for CRC screening. This focus on patient experience is the definition of patient-centric innovation. The C-Scan system, an ingestible, capsule-based device using low-dose X-rays, was designed to overcome the compliance issues associated with traditional colonoscopies. This is a huge hurdle in preventative care.

The commitment here is clear: reduce patient discomfort to improve early detection rates. To be fair, the company's enterprise value was negative $11.8 million as of early 2025, but the market's initial interest in the C-Scan concept, which sparked a stock price surge of 33.33% on January 3, 2025, proves the value of this patient-first approach. The challenge now is carrying that same innovative spirit into the new MBody AI Ltd. entity, ensuring the AI solutions remain focused on accessible, effective healthcare. You can read more about the company's foundational goals here: Check-Cap Ltd. (CHEK): History, Ownership, Mission, How It Works & Makes Money.

Scientific Rigor and Adaptability

Scientific rigor means a dedication to clinical validation, but in a clinical-stage company, it also means adapting when the data or market dictates a change. Check-Cap Ltd. was a clinical-stage diagnostics company, meaning its focus was on demonstrating the safety and efficacy of C-Scan through trials. This requires immense scientific discipline.

However, the most telling action in 2025 was the strategic adaptability. For the fiscal year ended December 31, 2024, the company reported approximately $0 in net Research and Development (R&D) expenses, a 100% decrease from the prior year's $8.3 million. This wasn't a failure of rigor, but a hard-nosed decision to pause C-Scan development and conserve capital, leading directly to the September 2025 merger agreement with MBody AI Corp. This move shows a pragmatic commitment to survival and a pivot to a new, promising scientific frontier-AI in diagnostics. That's a move I'd call 'adapt or die' realism.

Ethical and Strategic Stewardship

Stewardship is about managing capital and strategy for the long-term benefit of shareholders and the mission. Given the company's accumulated deficit of $170.0 million as of December 31, 2024, and a net loss of $25.1 million for that year, the board faced a clear financial reality. You simply cannot keep burning cash on a single, capital-intensive project indefinitely.

The decision to merge with MBody AI Corp, which shareholders approved on November 17, 2025, with 98.01% of votes in favor, was the ultimate act of strategic stewardship. It was a clear action to preserve shareholder value by integrating into a new, high-growth area and securing a future for the company's listing. The transaction also included an approved reverse share split, a necessary, if painful, step to maintain NASDAQ compliance. This is how a seasoned management team translates the value of 'ethical practices' into concrete financial action:

• Secured a merger with MBody AI Corp to pivot the business.
• Approved a reverse share split (ratio between 1-for-14 to 1-for-100) to stabilize the stock.
• General and administrative costs were held relatively steady at approximately $9.5 million in 2024, showing cost discipline.

The new entity, soon to be MBody AI Ltd., has a mandate to build on this strategic foundation, proving that careful financial management is a core value, too.